Literature DB >> 32074609

Tisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the Median.

Marco Chiumente1, Daniele Mengato2, Andrea Messori3.   

Abstract

Entities:  

Year:  2020        PMID: 32074609     DOI: 10.1159/000505891

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


× No keyword cloud information.
  2 in total

1.  CAR-T treatment: Determining the progression-free survival gain in patients with heavily pretreated multiple myeloma.

Authors:  Andrea Messori
Journal:  EJHaem       Date:  2020-07-13

2.  Dynamic RMST curves for survival analysis in clinical trials.

Authors:  Jason J Z Liao; G Frank Liu; Wen-Chi Wu
Journal:  BMC Med Res Methodol       Date:  2020-08-27       Impact factor: 4.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.